# iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS - from the same manufacturing donor batch, without genetic engineering.

*biotech · news · 2026-05-12 · The Manila Times*

## Key points

- agenT-797 produces distinct immune responses in cancer and ARDS using the same unmodified donor batch.
- The therapy drives pro-inflammatory TH1 activation in solid tumor patients but anti-inflammatory TH2 responses in ARDS.
- Clinical use showed complete metastatic cancer remission and improved survival in severe ARDS without genetic engineering.
- The manufacturing platform enables large-scale expansion of iNKT cells, reproducible across disease indications without engineering.
- A randomized Phase 2 trial in acute lung injury (C-1300-02) is underway with initial data expected in 2026.

**Companies:** MiNK Therapeutics, Inc.
**Countries:** United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/12/tmt-newswire/globenewswire/mink-therapeutics-presents-clinical-evidence-that-a-single-off-the-shelf-inkt-cell-product-drives-context-dependent-immune-responses-at-asgct-2026/2341644)

---

Canonical: https://newsio.io/n/21642f34-1a5d-4d18-a1a8-adfab22af7f2/inkt-therapy-agent-797-delivers-context-dependent-immune-reprogramming-showing-a
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works